Astellas Pharma Inc. (TYO:4503)
Japan · Delayed Price · Currency is JPY 2,484.50
-117.00 (-4.50%)
At close: Mar 2, 2026
Astellas Pharma Revenue
Astellas Pharma had revenue of 571.21B JPY in the quarter ending December 31, 2025, with 10.40% growth. This brings the company's revenue in the last twelve months to 2.06T, up 10.33% year-over-year. In the fiscal year ending March 31, 2025, Astellas Pharma had annual revenue of 1.91T with 19.25% growth.
Revenue (ttm)
2.06T
Revenue Growth
+10.33%
P/S Ratio
2.16
Revenue / Employee
151.04M
Employees
13,643
Market Cap
4.45T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.91T | 308.65B | 19.25% |
| Mar 31, 2024 | 1.60T | 85.05B | 5.60% |
| Mar 31, 2023 | 1.52T | 222.46B | 17.16% |
| Mar 31, 2022 | 1.30T | 46.64B | 3.73% |
| Mar 31, 2021 | 1.25T | -51.32B | -3.94% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Otsuka Holdings | 2.47T |
| Daiichi Sankyo Company | 2.05T |
| Chugai Pharmaceutical | 1.26T |
| Ono Pharmaceutical | 509.35B |
| Kyowa Kirin | 496.83B |
| Santen Pharmaceutical | 287.99B |
| JCR Pharmaceuticals | 37.55B |
| Perseus Proteomics | 140.41M |
Astellas Pharma News
- 6 days ago - Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish - Seeking Alpha
- 6 days ago - What's Happening With VIR Stock? - Forbes
- 7 days ago - Astellas collaborates with Vir to develop its experimental prostate cancer drug - Reuters
- 7 days ago - Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer - PRNewsWire
- 20 days ago - India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US - Reuters
- 6 weeks ago - Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines - GlobeNewsWire